Controversies in osteoporosis management: Concerns about bisphosphonates and when are "drug holidays" required?

Clinical Obstetrics and Gynecology

Volumn 56, Issue 4, 2013, Pages 743-748

  Mcclung, Michael ^a  

^a OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Atypical femoral fracture; Bisphosphonates; Drug holiday; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; ATYPICAL FEMORAL FRACTURE; BONE PAIN; BONE TURNOVER; CANCER RISK; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMUR FRACTURE; FRACTURE; HEART ATRIUM FIBRILLATION; HEARTBURN; HUMAN; IRITIS; JAW OSTEONECROSIS; LONG TERM CARE; MORTALITY; MYALGIA; NAUSEA; OSTEOPOROSIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREMENOPAUSE; SPINE FRACTURE; STRESS FRACTURE; TREATMENT DURATION; UVEITIS;

ATRIAL FIBRILLATION; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; WITHHOLDING TREATMENT;

EID: 84887691042     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3182a98295     Document Type: Article

References (34)

1. McClung MR, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug ''holiday''. Am J Med. 2013;126: 13-20.
2. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-135.
3. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004;20:433-439.
4. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
5. Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States. J Natl Cancer Inst. 2008;100: 845-853.
6. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27:2544-2550.
7. Black DM, Delmas PD, Eastell R, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356: 1809-1822.
8. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357: 1799-1809.
9. Federal Drug Administration. Update of safety review follow-up to the October 1, 2007. Early communication about the ongoing safety review of bisphosphonates. Available at: Http://www. fda.gov/Drugs/DrugSafety/ PostmarketDrugSafety InformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm136201. htm. Accessed September 12, 2013.
10. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360:89-90.
11. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304:657-663.
12. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of the oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ. 2010;341:c444.
13. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: Series of nested case-control studies with QResearch and CPRD data. BMJ. 2013;346:f114.
14. FDA. FDA Drug Safety Communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer. Available at: Http://www. fda.gov/Drugs/DrugSafety/ucm263320.htm. Accessed September 12, 2013.
15. Cardwell CR, Abnet CC, Veal P, et al. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. 2012;131:E717-E725.
16. Passarelli MN, Newcomb PA, Lacroix AZ, et al. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. J Bone Miner Res. 2013;28:2043-2048.
17. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28: 3582-3590.
18. Coló n-Emeric CS, Mesenbrink P, LylesKW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25:91-97.
19. Bolland MJ, Grey AB, Gamble GD, et al. Effect of osteoporosis treatment on mortality: A metaanalysis. J Clin Endocrinol Metab. 2010;95: 1174-1181.
20. Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96:1006-1014.
21. Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: A prospective five-year study. Osteoporos Int. 2011;22: 2551-2556.
22. Beaupre LA, MorrishDW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983-991.
23. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
24. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-Associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22: 1479-1491.
25. Hellstein JW, Adler RA, Edwards B, et al. American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142:1243-1251.
26. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.
27. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80: 413-415.
28. Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52:360-365.
29. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA. 2006;296:2927-2938.
30. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-254.
31. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remain reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19: 365-372.
32. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis - where do we go from here?. N Engl J Med. 2012;366:2048-2051.
33. Seeman E. To stop or not to stop, that is the question. Osteoporos Int. 2009;20:187-195.
34. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-1565.